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Hematopoietic nichePostnatal skeletal stem cells are a unique class of progenitors with biological properties that extendwell beyond the
limits of stemness as commonly deﬁned. Skeletal stem cells sustain skeletal tissue homeostasis, organize andmain-
tain the complex architectural structure of the bonemarrowmicroenvironment and provide a niche for hematopoi-
etic progenitor cells. The identiﬁcation of stem cells in the human post-natal skeleton has profoundly changed our
approach to the physiology and pathology of this system. Skeletal diseases have been long interpreted essentially
in terms of defective function of differentiated cells and/or abnormal turnover of the matrix that they produce.
Thenotion of a skeletal stem cell has brought forthmultiple, novel concepts in skeletal biology that provide potential
alternative concepts. At the same time, the recognition of the complex functions played by skeletal progenitors, such
as the structural and functional organization of the bone marrow, has provided an innovative, unifying perspective
for understanding bone and bone marrow changes simultaneously occurring in many disorders. Finally, the possi-
bility to isolate and highly enrich for skeletal progenitors, enables us to reproduce perfectly normal or pathological
organ miniatures. These, in turn, provide suitable models to investigate and manipulate the pathogenetic mecha-
nisms of many genetic and non-genetic skeletal diseases. This article is part of a Special Issue entitled Stem
cells and Bone.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Post-natal stem cells self-renew and differentiate to replenish the
mature cell compartments of the tissues in which they reside. The
very fact that stem cells for bone reside in bone marrow may sufﬁce to
highlight the fact that bone and bone marrow are functionally andolecolare, Sapienza Universita'
nucci).
. This is an open access article underanatomically continuous with one another. The continuity of bone and
bonemarrow is best reﬂected in the use of the term bone/bonemarrow
organ, which Maureen Owen introduced as the existence of a common
progenitor for all skeletal tissues in the bonemarrow emerged [1]. Bone
and bone marrow share their vascularity, which includes vessels tra-
versing the boundaries between bone and marrow space in both direc-
tions and often originating from and returning to the bonemarrow after
looping through bone. In situ, stem cells for bone are perivascular cells
[2,3], and at least some of the deﬁning phenotypic features of
perivascular progenitors in the bonemarrow are shared by perivascularthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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which represent the canonical differentiation pathways of bonemarrow
stromal progenitors, are both perivascular events, as both osteoblasts
and adipocytes are themselves perivascular cells. These simple facts
would suggest that any attempt to understand the pathophysiology of
bone in terms of cell dynamics should not exclude consideration of
the bone marrow. However, the dominant paradigm adopted in pursu-
ing an understanding of bone pathophysiology at the cellular level has
been centered for years on the dynamics of osteoblasts and osteoclasts.
On the other hand, and understandably enough, the dominant view of
stem cells in bone has been centered, as in other ﬁelds, on the potential
use of stem cells as therapeutic tools: replacement bricks for bone tissue
engineering, or perhaps vehicles for gene therapy (as successfully pur-
sued in other ﬁelds) in what is commonly referred to as “innovative
therapies” as part of “regenerative medicine.” However, in all systems,
the notion of stem cells is per se coupled to an appreciation that differ-
entiated tissues are part of a lineage, and that diseases of a given system,
in turn, can be seen as diseases of differentiated cells, or of the lineage as
a whole; and may reﬂect inherent dysfunction of differentiated cells or
of lineages, as well as secondary effects of exogenous signals, regulators
or cues. Pathogenic effects of a gene defect can bemanifested in mature
cells only, as is the case, for example, in sickle cell anemia; or conversely,
they can affect the entire lineage, as for example in thalassemia. The fol-
lowing pages are devoted to a brief discussion of how the notion of stem
cells in bone can be bent to proﬁt not only for treating, but also for un-
derstanding diseases, based on the assumption that proper understand-
ing is key to effective therapy. In doing so, we will adhere to the dual
nature and function of skeletal stem cells, which act as progenitors,
and act as non-progenitors [5]. Skeletal stem cells (also known as
bonemarrow-derived “mesenchymal” stem cells) generate all different
lineages that together comprise the skeleton, and those lineages only. At
the same time, they organize the vasculature of bone and bonemarrow
[2], establish the microenvironment for growth and differentiation of
hematopoietic cells and establish the “niche” for hematopoietic stem
cells (HSCs) [2,3,6]. This notion comes originally from studies using
human cells and reﬁned in vivo transplantation approaches [2], which
were then conﬁrmed in their key conceptual advances by a wealth of
subsequent studies in themouse, either using similar approaches, or ge-
netic tools, or combinations of both [3,7–11]. At this time, efforts are
being made to elucidate the potential diversity of local bone marrow
territories with respect to hematopoietic functions, and the speciﬁc
functions of putative (and as yet, not conclusively identiﬁed) stromal
subsets, or non-stromal cell types such as endothelial cells [10,12,13]
or neural cells [14,15]. However, recent data in the mouse directly sup-
port the general key concept that perivascular stromal skeletal stem
cells (otherwise known as bone marrow-derived “mesenchymal” stem
cells [16]) act both as progenitors for skeletal tissues and as key players
of the perivascular HME/niche also in themouse [11,13]. Themanner in
which the function of skeletal stem cells is probed in the human system
[i.e., heterotopic transplantation, also of clonal, single cell-derived pop-
ulations [reviewed in [16]], to the effect of recapitulating the organo-
genesis of bone, illustrates these functions and their unique nature
most effectively, in sharp contrast with other types of stem cells. Trans-
plantation is the mainstay of stem cell biology. Transplantation of HSCs
results in reconstitution of hematopoiesis; transplantation of epithelial
stem cells in the reconstitution of epithelial tissues; transplantation of
pluripotent embryonic stem cells results in teratomas (i.e., in the chaotic
admixture of all differentiated lineages); transplantation of skeletal
stem cells results in the generation of different skeletal tissues, yes,
but also in a highly coordinated, mutual organization of donor tissues
with host tissues in a chimeric organoid [2,5,6].
Skeletal stem cells are found in the bone marrow stroma. In situ, the
bone marrow stroma is a highly elusive tissue, due to the simple fact
that the key cell type, the adventitial reticular cell, escapes detection in
conventional histological sections, and can only be visualized using a cy-
tochemical stain (alkaline phosphatase) [17–19] or immunocytochemicalmarkers (e.g., CD146, CD105, CD90) [2]. Changes in number, density, phe-
notype and function of stromal cells result in gross changes in the organi-
zation of the bone marrow stroma, which accompany changes in bone.
Osteoporosis, the most common bone disease, is not only a reduction in
bone mass, it is also an increase in marrow adiposity and a reduction in
alkaline phosphatase expressing stromal cells [20]. Endosteal ﬁbrosis of
secondary hyperparathyroidism is the local accumulation of bone mar-
row stromal cells at the endosteum [21,22]. The ﬁbrosis of ﬁbrous dyspla-
sia of bone (FD) is the local accumulation of stromal cells in an abnormal
marrow space [23], is coupled to the loss of adipocytes and of the hema-
topoietic microenvironment, and also to profound subversion of bone ar-
chitecture, matrix composition, mineralization, internal texture and
mechanical competence. Vascularity of the bonemarrow is profoundly al-
tered in osteoporosis, Paget's disease, FD, and many more bone diseases.
Many more examples could be given illustrating the point that calling
an individual disease a “bone disease” rather than a “bone marrow dis-
ease” can be seen as the result of a conventional choice, or simply of a bias.
Skeletal stem cells and genetic diseases
The introduction of the induced pluripotent stem (iPS) cell technology
[24] was saluted with enthusiasm as it conveyed both a reliable techno-
logical tool for generating pluripotent cells and theoretically any differen-
tiated lineage, and relief from a heated “ethical” controversy, while
illustrating the extraordinary notion that less than a handful of genes
could reprogram an adult cell into pluripotency. Shortly thereafter, the
value of iPS cells as tools formodeling disease becamewidely appreciated
[25], and currently predominates over the still immature use of iPS cells
for direct replacement of diseased tissues. The use of iPS cells for disease
modeling encompasses investigative as well as directly applicative ave-
nues: the generation of patient-speciﬁc diseased and differentiated cell
types, in which to seek disease mechanisms, but also a tool for high-
throughput drug screening. iPS cells have been used to model rare dis-
eases such as Fibrodysplasia Ossiﬁcans Progressiva [26] and metatropic
dysplasia [27], revealing altered patterns of cartilaginous differentiation
through the use, notably, of assays in fact developed for the study of post-
natal stem cells. However, the notion that skeletal diseases could be
modeled through stem cells precedes the development of the iPS cell
technology. Based on the recognition that obvious changes in the bone
marrow stroma occur in FD, Bianco et al. [28] hypothesized that hetero-
topic transplantation of stromal cells fromthe abnormalmarrowof FDpa-
tients could recapitulate in vivo the abnormal architecture of FD bone and
bone marrow. This provided evidence that a human non-neoplastic dis-
ease could be transferred to immunocompromised mice, and also the
ﬁrst use of stem cells for transferring disease into the mouse. A few
years before, John Dick and coworkers had shown that human leukemia
could be transferred to SCID/bg mice, through the transplantation of leu-
kemic cells [29,30]; from these studies, the concept that cancer could be
transferred to immunocompromised mice by putative cancer stem cells,
and the very idea of cancer stemcells,was to arise later [31]. The same ap-
proach as used for FD contributed decisively to identify and name
Gnathodiaphyseal Dysplasia as a separate disease, distinct from both FD
and Osteogenesis Imperfecta, and to predict from the cell-autonomous
properties of stromal progenitors [32], its genetic nature, which was to
be identiﬁed shortly thereafter [33]. Speciﬁc dysfunction in skeletal and
dental progenitors was recognized in Cleidocranial Dysplasia [34], while
heterotopic transplants of stromal progenitors frompatientswithHurler's
disease, conversely, dispel an inherent disruption of stromal cell differen-
tiation [35]. However, the use of novel types of heterotopic transplanta-
tion assays [6] reveals speciﬁc changes in cartilage metabolism in
Hurler's disease (Seraﬁni et al., manuscript in preparation). Heterotopic
transplantation of stromal progenitor cells serves also to demonstrate
in vivo the functional impact of gene knockout or of transgenes [36,37].
The adoption of stemcells as amodel of disease has been remarkably
productive in the speciﬁc area inwhich it wasmost intensively pursued,
Fibrous Dysplasia. Use of cultures of FD-derived bone marrow stromal
Fig. 1.Heterotopic transplantation of a spontaneously immortalizedmurine bonemarrow stromal cell line, demonstrating sarcomatous growth (HA/TCP, hydroxyapatite/tricalcium phosphate
carrier).
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tiﬁcation of the causative GNASmutations [28,38], and for the quantiﬁ-
cation of the mutational load in a somatic mosaic disease [39].
Correlation of quantitative estimates of mutational load with patient
age and clinical and pathological assessment of organ lesions led to
the recognition that GNAS-mutated and wild-type stromal progenitors
have different lifespans and self-renewal kinetics, explaining the natural
occurrence of a spontaneous sterilization over time of the bonemarrow
progenitor compartment from the disease gene in some patients [40].
Using clonal populations of GNAS-mutated stromal progenitors, it was
also possible to determine the imprinting proﬁle of GNAS transcripts
in skeletal progenitors. This revealed that while alternative transcripts
of GNAS are expressed in osteoprogenitors and imprinted, Gsα is asym-
metrically expressed in different clones in a random fashion, indepen-
dent on imprinting, but potentially contributing to disease
heterogeneity [41]. Finally, recognition of FGF23 as a product of the os-
teogenic lineage, and consequently of the role of bone as an endocrine
organ regulating phosphate metabolism in the kidney, came from the
use of stromal osteoprogenitors as an in vitro and in vivo model of FD.
Overproduction of FGF23 in FD can account for the occurrence of
hypophosphatemic rickets/osteomalacia in patients with severe
panostotic forms of the disease [42].
One of the most challenging, and at the same time attractive, facets
of the stem cell notion is the prospect of being able to tackle systemic
genetic diseases of the skeleton. Osteogenesis Imperfecta was the ﬁrst
disease for which a stem cell-based type of interventionwas envisioned
[43], and in which targeting the genetic defect in stem cells ex vivo was
attempted [44,45]. The gene defect causing FD is a dominant, gain-of-
function point mutation in a ubiquitously expressed, indispensable
gene. Gene correction in FD thus requires silencing of themutated allele
with absolute speciﬁcity, which per se is a greater challenge in gene
therapy than gene replacement. Nonetheless, the FD-causing mutation
can be efﬁciently and speciﬁcally corrected in human stromal progeni-
tor ex vivo using lentivirally expressed shRNAs, resulting in reversionof the fundamental cellular phenotype represented by excess produc-
tion of cAMP [46]. Of note, as speciﬁc genetic defects can be corrected
ex vivo in skeletal stem cells, several systemic, often lethal, skeletal dis-
eases such as Osteogenesis Imperfecta and FD could be cured as of
today, if systemic infusion of skeletal stem cells was at all feasible in
the simplistic way in which it was ﬁrst envisioned. Unfortunately, we
are not there yet. Nonetheless, the use of stem cells, including gene-
corrected stem cells for treating systemic diseases of the skeleton re-
mains unfeasible until ways to deliver stem cells systemically to the
skeleton becomes feasible. Conversely, stable transduction of normal
stromal progenitors with disease genes using last generation lentiviral
vectors provides an additional tool for investigating the functional ef-
fects of a disease gene. In the case of FD, this exercise revealed, for exam-
ple, the induction of RANKL as a robust and speciﬁc effect of the GNAS
mutation, directly relevant to the origin of excess osteoclastogenesis
and remodeling in FD [46], and made it possible to investigate the tran-
scriptome of newlymutated cells with appropriate controls and statisti-
cal robustness, circumventing the unpredictable variability of primary
cultures derived from clinical material (manuscript in preparation).
Skeletal stem cells and cancer
Hematopoietic and non-hematopoietic cancer (primary and second-
ary) is a major determinant of skeletal morbidity, and for this reason,
cancer in bone is the source of major clinical, social and healthcare con-
cerns. Until very recently, myeloma and metastatic growth of primary
epithelial cancers were the speciﬁc focus of interest, reﬂecting both
the occurrence of gross bone lesions as a result of their growth, and of
the ease with which such lesions could be traced to an unbalance in re-
modeling. In this context, interest in the interaction of cancer cells with
bone essentially excluded consideration of a potential role for skeletal
stem cells as partners or players of the cancer–bone interaction, and in
most cases even consideration of a role for bone marrow stromal cells
at large. The notion of stem cells in bone currently contributes to
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the biology of bone cells, and to changing the visual angle on the inter-
actions of cancer and bone at the cellular andmolecular levels. In gener-
al, a role of skeletal stem cells in cancer can be seen as running in parallel
with their dual physiological functions — as progenitors of skeletal tis-
sues and as providers and organizers of a microenvironment. The pro-
genitor function comes into play in understanding the origin of
primary bone tumors; the non-progenitor functions come into play in
understanding how skeletal progenitors contribute to the establish-
ment of hematopoietic and non-hematopoietic malignancies (bone
metastasis).Primary bone tumors
Skeletal stem cells may represent direct progenitors of sarcomas. In
spite of the identiﬁcation of speciﬁc molecular pathways underpinning
speciﬁc types of bone tumors, classical and predominant (and to some
extent, partially obsolete) paradigms of histogenesis of bone tumors
have largely remained indifferent to the notion that skeletal tissues em-
anate from a common progenitor. As a result, classiﬁcation and text-
books of pathology still identify primary bone tumors based on their
predominant phenotype and/or clinical behavior. However, recent
work has highlighted the signiﬁcance of skeletal progenitor cells for un-
derstanding the biology of bone tumors. Transformation ofmurine bone
marrow stromal cells in culture is a far more common event than cur-
rently appreciated (perhaps accounting for some reports of extraordi-
nary numbers of population doublings, mistaken as “self-renewal” in
some reports). Screening of multiple murine “MSC” lines by in vivo
transplantation assays (conducted to probe their osteogenic capacity)
easily reveals their tumorigenic properties (our unpublished results)
(Fig.1). The latter, in turn, are easily conceived of as the effect of the
known chromosomal instability characteristic of murine cell cultures,
at variance with humans. Spontaneous immortalization in cultures of
human BMSCs, regardless of sporadic reports [47], is admittedly an ex-
ceptional event, reﬂecting uncontrolled growth conditions. More im-
portantly, while forced expression of hTERT in human skeletal stem
cells can boost their osteogenic capacity [48,49], prolonged culturing
of hTERT-immortalized human skeletal progenitors results in multiple
genetic hits that may culminate with acquisition of full-blown tumori-
genesis as assayed by in vivo transplantation [50]. By suggesting that in-
ordinately high rates of proliferation over prolonged time can lead to
transformation of skeletal progenitors, these data provide a direct
viewof sarcomagenesis as related to skeletal stem cells. More speciﬁcal-
ly, a pathogenetic link between Ewing's sarcoma (a highly malignant
bone tumor, EWS) and skeletal progenitors has been suggested recent-
ly. The transformation of murine “mesenchymal” (skeletal) stem cells
by EWS-FLI1 (the fusion gene underpinning familial forms of EWS) gen-
erated EWS-like tumors [51]; conversely, the silencing of EWS-FLI1 in
EWS cell lines rescued neoplastic cells to a “mesenchymal” cell pheno-
type and function [52]. Suva et al. also isolated a CD133 positive subpop-
ulation of stem cells from EWS that was able to initiate the growth of
serially transplantable tumors (a putative cancer stem cell) while
retaining the ability to differentiate along the adipogenic, osteogenic,
and chondrogenic lineages [53]. A direct involvement of skeletal pro-
genitors in tumorigenesis has also been hypothesized for murine and
human osteosarcoma. Mohseny et al. generated a murine “mesenchy-
mal” stem cell system that formed osteosarcoma in vivo reproducing
clinically relevant genetic aberrations [54], and osteosarcoma cell lines
have been generated from transformed human “MSCs” [55]. Cells simi-
lar to skeletal stem cells, characterized by high invasiveness and drug
resistance, have been isolated from human and murine tumors by
using STRO1 and CD117 asmarkers [56]. It must bementioned, howev-
er, that other studies have questioned the pathogenetic relevance of
“MSCs” in both EWS and osteosarcoma, suggesting that “MSCs” are
the major non-malignant component of the tumoral stroma [57,58].Skeletal stem cells and the cancer microenvironment
While the idea that the bone marrow stroma as a whole provides a
microenvironment for hematopoiesis and a niche for HSCs (the HME)
goes back to classical hypotheses and experimental work, a revived in-
terest in bone cells as niche-maintaining cells arose in the last ten years,
prompting investigation of the “niche” as a determinant of tumor
growth in bone. Later, a speciﬁc role for stem cells of the skeleton in pro-
viding the HME and niche functions became apparent, placing stromal
osteoprogenitors at center stage of cancer–bone interactions (reviewed
in [4,59]). In the background, the classical “seed and soil” hypothesis of
Stephen Paget [60] taken as a paradigmof the elective tropismof certain
types of cancer for bone applies in a similar way to the interaction of
blood-borne hematopoietic progenitors with an HME. Direct identiﬁca-
tion of skeletal stem/progenitor cells as the cells establishing the HME/
niche, and of their own residence in a perivascular niche, thus highlights
the potential key role of skeletal progenitors in the homing and growth
of cancer in bone.
Currently, the terms “niche” and “microenvironment” tend to be
used interchangeably. However, even though bone marrow stromal
progenitors may exert both functions, the two functions are distinct.
The ability of certain types of cancer to home to, and grow in bone selec-
tively, can reﬂect either the ability of the bone/bone marrow organ to
provide a “niche” for cancer-initiating cells, or to provide a microenvi-
ronment suitable for the growth of their progeny. In the ﬁrst instance,
the existence of a cancer stem cell (CSC) is postulated. However, the
concept of a CSC remains controversial for most types of tumors in
which the emergence of cells endowed with tumorigenicity in the im-
munocompromised mouse, and of metastatic potential, is not at all a
property of the cells that initiate the primary tumor growth (human pa-
thology provides a whole repertoire of examples, from the progression
of melanoma to the development of invasiveness in epithelial cancers).
Indeed, CSCs for non-hematopoietic cancer are probed by heterotopic
xenotransplantation of limiting numbers of putative CSCs in immuno-
compromised mice, outside of a niche. Tumorigenicity in immunocom-
promised mice (the mainstay of any demonstration of CSCs) coincides
with the ability of a cancer subclone (ametastatic subclone) to grow ef-
ﬁciently outside of their original microenvironment, independent of it,
or in a different microenvironment. For this reason, one might argue
(against the ﬂow of a portion of the current literature) that demonstra-
tion of a CSC in most instances coincides with demonstration of the dis-
pensability of the primary niche. There is, conversely, little doubt of the
fact that most hematopoietic cancers grow primarily in the bone/bone
marrow organ, and some types of both hematopoietic (lymphoma)
and non-hematopoietic cancer have an exquisite tropism for bone as a
secondary site.
Hematopoietic cancer
The speciﬁc role for bonemarrow stromal progenitors in supporting
the growth of hematopoietic cancer can be as diverse as the variety of
hematopoietic cancers themselves, and can directly reﬂect on the pat-
tern of their growth and the type of local organ damage they can pro-
duce. In multiple myeloma, for example, the CXCL12/CXCR4 axis,
which is thought to operate in the recruitment of a variety of blood
borne cells including circulating cells from epithelial cancer and normal
HSCs, can account for both the recruitment of myeloma cells to bone
marrow and the promotion of their local survival [61,62]. Myeloma
cells are thought to represent post-germinal center B cells with somatic
hypermutation and a phenotype consistent with memory B cells [63],
which in awaymakesmyeloma a unique kind of “metastatic-only” can-
cer that involves selectively the bone marrow but may not arise within
it. The unique ability ofmyeloma to produce lytic lesions in bone, on the
other hand, can in turn be traced to different mechanisms, in turn cen-
tered on the interaction of myeloma cells with stromal
osteoprogenitors. Dickkopf-1 (DKK-1), a Wnt antagonist, is involved
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while RANKL overexpression and downregulation of osteoprotegerin
in stromal cells are intuitively linked to promotion of bone resorption
culminating in the production of osteolytic lesions [64]. A number of ad-
ditional mechanisms can, however, contribute to this effect, including
the generation of Th17 cells, immune inhibition of clonal growth in
the pre-myelomatous monoclonal gammopathies of undeﬁned signiﬁ-
cance (MGUS), and modulation of macrophage and dendritic cell func-
tion. The role of stromal progenitors in most of these mechanisms is
conceivable but remains to be deﬁned [65].
The distinct patterns of bone marrow involvement by non-Hodgkin's
lymphomasprovide thebest visual illustration of the existence of spatially
deﬁned microenvironments in the bone–bone marrow organ, sought by
distinct populations of cancer cells. Follicular lymphoma grows as
paratrabecular nodules, whereas marginal zone lymphomas and other
types (hairy cell leukemia, mantle cell lymphoma) characteristically inﬁl-
trate sinusoids. Tumor-speciﬁc patterns of adhesion molecule expression
mayunderpin such speciﬁc tropism for distinctmicroanatomical sites, the
speciﬁc stromal composition of which remains to be elucidated. The my-
eloﬁbrosis and osteosclerosis seen in myeloproliferative neoplasms
(MPNs), in turn, represent the best visual demonstration of the involve-
ment of stromal osteoprogenitors in the profound changes occurring in
the hematopoietic microenvironment and niche in MPNs. Notably, the
appearance of intravascular and extramedullary hematopoiesis in prima-
ry myeloﬁbrosis may be linked to a profound subversion of the CXCL12/
CXCR4 axis, which normally directs homing of HSCs to themarrow extra-
vascular environment [66]. Human [2] and murine [8,67] perivascular
osteoprogenitors are the prime source of CXCL12 in the perivascular/ex-
travascular environment in bone marrow; stromal osteoprogenitors in-
crease in number in primary myeloﬁbrosis (PMF) [68], but local
availability of CXCL12 is decreased due to enhanced clearance andproteo-
lytic degradation, and expression of CXCR4 inHSCsmay be decreased [69,
70].
A host of interactions betweenmyeloid cancer cells and stromal pro-
genitors have been described, highlighting a complex bidirectional in-
terplay involving a variety of pathways such as Wnt and adhesion
molecule-conveyed signals [71]. Here too, the role of stromal-derived
CXCL12 is pivotal in a number of key events [72] Changes in the function
of stromal progenitors induced by cancer cells in turn result in tissue
changes such as ﬁbrosis and perturbation of niche/microenvironment
effects on normal hematopoiesis [73,74]. Likewise, hematopoietic can-
cer may alter the function of additional cell types that may normally
contribute to a functional “niche”/HME effect, ultimately resulting in
promotion of cancer growth [15]. No doubt, themost intriguingﬁndings
are those suggesting a primary role of osteoprogenitors in directing the
leukemogenic process itself. These include the observation of genetic
changes in stromal cells in patients with myelodysplasia [75,76],
mouse models of myeloproliferative neoplasia secondary to genetic
changes in the stroma [77], and induction of myelodysplasia and leuke-
mia in mice as a result of Dicer-1 knockout in osteoprogenitors proper
[9]. These data illustrate at the same time a speciﬁc “niche” (as opposed
to microenvironment) effect as a function of osteoprogenitors proper.
Bone metastasis
Conceptual models for elucidating the interplay between non-
hematopoietic cancer and bone (as a source of major morbidity in cancer
patients) have been inscribed in a general paradigm inwhich remodeling
of bone through the regulated action of differentiated bone cells is the key
physiological event. Nodoubt, ultimate disruption of the balance between
formation and resorption of bone is convenient to explain the osteolytic
or osteosclerotic effects of bone metastasis [reviewed in [78]]. It must be
noted, however, that while directly underpinning bone morbidity, these
events come late in the natural history of metastatic growth in bone,
and exclude from consideration the critical interplay between blood-
borne cancer cells and the local microenvironment that lead to homingof cancer cells to bone (and its marrow) in the ﬁrst place [79,80]. Down-
streamof homing, dormancy of cancer cells [81,82], or their growth into a
sizable metastatic deposit, are alternative events. One might argue that
the former illustrates a “niche” function, while the latter rather reﬂects a
“microenvironment” effect. The bonemarrow is the repository of circulat-
ing tumor cells [83–86] even in the absence of, or prior to, the establish-
ment of metastasis. All bone metastasis result from the seeding of
cancer cells in the bone marrow. Redirecting the focus on early steps of
themetastatic process may have obvious applicative and clinical implica-
tions, and it implies redirecting the attention on the interaction of cancer
cells with stromal progenitors. Capturing the early events of themetasta-
tic process in clinical material is difﬁcult. Analysis of bone marrow biop-
sies taken from patients with known or unknown primary cancer, but
free from signs and symptoms of local involvement, is a convenient way
to visualize natural earlymetastasis in bone. This shows that conventional
distinctions between “lytic” or “sclerotic” types ofmetastasis do not apply
to early metastasis, in which an excess of medullary bone formation is a
regular event, independent of the type and site of primary cancer, and
therefore also of the gross “lytic” or “sclerotic” pattern that could be ulti-
mately expected in the single case. Although anumber of studies haveuti-
lized cultures of bone marrow stromal cells to model their interaction
with cancer cells, an in vitro approachdoes not easily capture thedynamic
events of cancer growth in a bone microenvironment. Attempts have re-
cently been made towards the transfer in vivo of stromal/cancer co-
cultures established ex vivo [87]. Current models of bone metastasis
mostly rely on the intracardiac injection of large numbers of cancer cells
[88,89]. This approachwas amajor advance over prior practices involving
the direct injection of cancer cells into bone, butwas essentially utilized to
analyze the gross effects of cancer growth in bone, andmaynot reﬂect ac-
curately the metastatic process in at least two respects: one, it bypasses
the venous phase of cancer cell circulation, and second, it analyzes the
ability of speciﬁc cancer cell lines to grow in amurinemicroenvironment.
Speciﬁc types of cancermay not grow as efﬁciently inmouse bone as they
do in a humanmicroenvironment, hence the need for humanizedmodels
[90]. This general approach is reﬂected into varied attempts to explore the
homing of prostate cancer (manuscript in preparation), myeloma cells
[91], leukemia [92], and breast cancer cells [93] to humanized
microenvironments.
Conclusions
Stem cells in bone bring forth a remarkable change of perspective in
bonemedicine. They allow for consideration of diseases that affect bone
as an organ rather than as a tissue. They provide the tool needed to un-
derstand diseases of the skeleton other than osteoporosis, while also
contributing to the understanding of osteoporosis and bone aging.
They provide a novel angle, centered on bone progenitors, in the study
ofmajor hematological diseases. They open the prospect of understand-
ing the interaction of bone and cancer using the understanding of the
HME/niche as a blueprint. Finally, pursuing these avenues of strictmed-
ical relevance can advance our understanding of bone disease, which
can feed back on our understanding of bone physiology.
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